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Abstract
One of the major applications of generative models for drug discovery targets the lead-
optimization phase. During the optimization of a lead series, it is common to have scaffold
constraints imposed on the structure of the molecules designed. Without enforcing such
constraints, the probability of generating molecules with the required scaffold is extremely
low and hinders the practicality of generative models for de-novo drug design. To tackle
this issue, we introduce a new algorithm to perform scaffold-constrained in-silico molecu-
lar design. We build on the well-known SMILES-based Recurrent Neural Network (RNN)
generative model, with a modified sampling procedure to achieve scaffold-constrained gener-
ation. We directly benefit from the associated reinforcement learning methods, allowing to
design molecules optimized for different properties while exploring only the relevant chemical
space. We showcase the methods ability to perform scaffold-constrained generation on vari-
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ous tasks: designing novel molecules around scaffolds extracted from SureChEMBL chemical
series, generating novel active molecules on the Dopamine Receptor D2 (DRD2) target, and
finally, designing predicted actives on the MMP-12 series, an industrial lead-optimization
project.
Introduction
Finding new drugs is a long, costly and difficult1 problem, with potential failure all along
the drug discovery pipeline and an overall success rate2 close to only 4%. Lead-optimization,
where medicinal chemists refine bioactive molecules into potential drugs, takes a major part
of the time and cost in the discovery pipeline. Finding a good drug candidate requires
finding a molecule that is active on the target of interest while satisfying multiple criteria
mainly related to safety and pharmacokinetics. In this respect, lead-optimization can be
viewed as a multi-objective optimization problem in chemical space. There has been a
recent surge of interest in generative models for de-novo drug design3 and their application
in the drug discovery pipeline. Generative models have been studied for two types of tasks:
distribution learning and goal-oriented learning.4 Distribution learning aims at reproducing
the distribution of a known dataset, in order to sample a large library of molecules similar to
the initial dataset used to train the generative model. Goal-oriented learning, on the other
hand, takes as input a scoring function and aims at finding the molecules with the highest
scores. Applying generative models to lead-optimization can actually be understood as a
special case of goal-oriented learning, where the scoring function reflects the adequacy of
the molecule to the different project objectives. Distribution learning benchmarks are also
frequently used to assess whether a model has learnt to generate drug-like molecules, and
will be a good starting point for goal-oriented learning.
However, real life lead optimization projects very often impose constraints on the scaf-
fold of designed molecules. Interesting scaffolds are identified during the lead identification
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phase of the pipeline, and often kept throughout the rest of the pipeline, with only minor
changes. The scaffold, or core of the molecule, is key to (i) preserving biological activity
identified earlier in the pipeline (ii) staying within areas of chemical space where prior infor-
mation gathered is relevant, making SAR (structure-activity relationship) understandable
(iii) maintaining a high throughput for compound synthesis by using common precursors,
speeding the Design-Make-Test-Analysis (DMTA) cycle to a level acceptable by industry
standards and (iv) exploring a relevant chemical space, translatable into a Markush struc-
ture, from an Intellectual Property perspective.
Therefore, lead-optimization is actually most of the time5 a multi-objective optimization
problem under scaffold constraints. Yet, goal-oriented learning with scaffold constraints is
not extensively studied, while being of major interest in the application of generative models
to medicinal chemistry. As showed in our work, simply including the presence of the scaffold
of interest in the scoring function as a supplementary criterion and applying existing goal-
oriented models6 shows poor results. Hence, there exists a clear need for algorithms that
include directly those constraints in their generative process.
Before the increasing rise of interest3 in generative models for chemistry, traditional
approaches were already studied by computational chemists for de-novo design of optimized
molecules. Those approaches relied either on combination of fragments and exploration of
chemical space by performing virtual reactions with handcrafted rules.7 Genetic algorithms,
that showed success in many optimization tasks, were also adapted to chemistry and used
in order to design molecules of interest.8,9 Following Gomez-Bombarelli et al.10 who applied
recent generative models in order to generate new molecules, there has been increasingly
growing interest3,11 for de-novo design with generative models. Indeed, relying on a data-
driven method that learns the underlying distribution of molecules helps to remain in a
chemical space of drug-like molecules.
Among the various molecular generative models published in recent years, many actu-
ally rely3 on RNN, and especially on the Long Short Term Memory (LSTM) architecture.
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RNN are frequently used as generative models for sequential data, and in particular for
SMILES.12,13 Those models differ by the way they aim at learning the probability distri-
bution of the training set. Variational Auto-Encoders (VAE)10,14 learn this distribution
through an encoder-decoder loss, where the generator is used as a decoder and another
RNN used as encoder. Generative Adversarial Networks (GAN)14,15 learn the distribution
through a competition between the generator and a discriminator, and character-level gen-
erator12,13 through simple negative log-likelihood minimization. While the methods to learn
the distribution differ, in the end those methods rely on the same architecture to generate
new molecules, which is SMILES-based RNN. To design optimized molecules with RNN,
the easiest way is to generate a large virtual library of molecules and then screen it against
the objectives, but the likelihood of finding optimized molecules is extremely small. Rein-
forcement Learning (RL) was proposed as a way to design optimized molecules.12 Either
through policy gradient or hill-climbing, which both aim at maximizing the probability of
the highest scoring SMILES, the RNN can be fine-tuned to generate high scoring molecules.
Hill-climbing was shown4 to achieve state-of-the-art results on various goal-oriented bench-
marks. Optimizing directly on the molecular graph, controlled either by a neural network16
or through Monte-Carlo Tree Search,9 can yield interesting results,4 but also leads to com-
pounds of lesser4 quality, which hinders adoption of those approaches for application in drug
discovery projects. Methods based on Graph Neural Networks, that work directly on the
molecular graph rather than with SMILES,17,18 have also been studied recently. Those ar-
chitectures are more experimental and havent proved for the moment to perform as well as
SMILES based methods.
Scaffold-constrained generation has been investigated in only a few previous works. Frag-
ment growing with RNN19,20 has been described, but is very limited in its scope and can-
not accommodate scaffold constraints besides simply imposing the presence of a fragment.
DeepScaffold21 relies on Graph Neural Networks to build molecules on an existing scaffold.
The architecture used is complex and experimental,22 relying on graph convolutional neu-
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ral networks. The absence of built-in reinforcement learning also hinders the adoption of
this method to design optimized molecules. The Reinvent Scaffold Decorator22 is based on
SMILES and RNN and uses an encoder-decoder architecture. It completes scaffolds in two
different ways, single-step and multi-step. Single-step completes all open positions at once,
while multi-step completes each open position iteratively. The architecture used is also com-
plex, as it relies on an encoder-decoder scheme, and is limited to open positions at branching
points. The model also requires dataset-specific preprocessing and training for each appli-
cation. Moreover, no RL procedure is directly applicable, limiting as well the scope of this
method.
Prior work on Markov models and especially RNN23,24 showed that for a given language,
constraints that can be translated sequentially can be enforced during sampling. Thus,
the main idea behind our model is that scaffold constraints can actually be translated to
the SMILES language. Acknowledging this fact, we investigate how we can leverage this
translation from structure to SMILES to perform scaffold-constrained generation. We show
that scaffold-constrained generation can be achieved with SMILES-based RNN using simply
a modified sampling procedure. This means that our method tackles scaffold-constrained
generation without the need for a new model, or even for retraining this model. More-
over, all previous experience acquired by computational chemists with SMILES-based RNN
usage translates with our procedure. The available state-of-the-art reinforcement learning
methods for goal-oriented learning ensures that our procedure is easily applicable for lead-
optimization. By performing scaffold constrained generation, we can include the project’s
structural constraints directly in our generative process. This allows us to search directly
within the very sparse subspace of chemical space that is relevant to the lead-optimization
project. Furthermore, our framework allows low-level control on scaffold-constrained molec-
ular generation, including the possibility to limit oneself to linear fragments, to control the
presence of branches and cycles, or the type of atoms authorized, as well as the ability to
perform scaffold-hopping.
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We begin by giving background on molecule generation with SMILES-based RNN. Then,
we show how to adapt the sampling procedure in order to perform scaffold constrained gen-
eration with an RNN. Finally, we provide experimental results on different de-novo design
tasks, and show the usefulness of our method in the context of scaffold constrained genera-
tion.
Methods
The SMILES25 language represents molecules as a chain of characters. Each character
corresponds to an atom or denotes structural information, such as opening or closing of
cycles and branches, stereochemistry or multiple bonds.
Starting from a molecular graph, cycles are broken down and marked with numbers, and
a starting atom is chosen. The SMILES string is obtained by printing the symbol of the
nodes encountered in a depth-first traversal starting at the chosen atom, with parentheses
indicating branching points in the graph. For a given molecular graph, there are as least as
many SMILES as possible starting atoms. A canonicalization algorithm25 can be used to pick
the starting atom, thus yielding the canonical SMILES of the molecule. The corresponding
molecular graph can be easily retrieved from a given SMILES.
RNN can generate SMILES in a sequential fashion by modeling the conditional proba-
bility distribution over SMILES tokens (conditioned on the beginning of a SMILES). The
SMILES language is enriched with a GO and EOS token12 that denote the beginning and
the end of a SMILES string. Let s = x0, ....xn the tokenized version of a SMILES string,
with xi characters from the SMILES language (here x0 and xt denote respectively the GO
and EOS tokens). The RNN models P (xt | x0, ...xt−1), i.e. the conditional probability of a
token given all the previous ones. The RNN is trained on a database of drug-like molecules
(such as ChEMBL26) to predict the next token of a SMILES given the beginning of the
sequence, and training is achieved through minimization of the negative log-likelihood of the
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training set SMILES. The objective is to minimize (w.r.t the RNN parameters denoted by
θ) the following loss:
L(θ) = −
T∑
t=1
logP (xt | x0, ...xt−1) (1)
The RNN relies on its internal state h to process the information from the previous tokens,
and models the conditional probability P (xt | x0, ...xt−1) as P (xt | ht−1). Data augmentation
by enriching the dataset with non-canonical SMILES27 has shown benefits in different tasks,
therefore we adopt it in our methodology when training RNN for the following experiments.
Once the conditional probability distribution P (xt | x0, ...xt−1) is learnt, sampling is
achieved by initializing the sequence with a GO token, and then sampling tokens sequen-
tially. This procedure ends when a EOS token is sampled, and returns a SMILES with its
corresponding likelihood, which is amenable to backpropagation.
Algorithm 1: Generating new SMILES samples
Result: SMILES string
initialize h0 ;
x0 = GO ;
t = 1 ;
while xt 6= EOS do
Sample xt from P (xt | x0, ...xt−1) and update ht−1 to ht;
t = t+ 1 ;
end
Output: x0, ...xt
This framework can be adapted to scaffold constrained generation. Indeed, a scaffold
can be viewed as an incomplete SMILES. This incomplete SMILES can have different po-
sitions with open possibilities, denoted by the special token *. An example of how scaffold
constraints can be translated in SMILES, in the case of an open branch, is given Table 1.
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Table 1: Linking SMILES syntax with molecular structure: open branch
Original structure Structure with open position
CC(C)(C(=O)O)c1ccc(cc1)C(O)CCC
N2CCC(CC2)C(O)(c3ccccc3)c4ccccc4
CC(C)(C(=O)O)c1ccc(cc1)C(O)CC
CN2CCC(CC2)C(O)(*)c4ccccc4
When the open position is within a linker, an example is given Table 2.
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Table 2: Linking SMILES syntax with molecular structure: open linker
Original structure Structure with open position
CC(C)(C(=O)O)c1ccc(cc1)C(O)CCCN
2CCC(CC2)C(O)(c3ccccc3)c4ccccc4
CC(C)(C(=O)O)c1ccc(cc1)C(O)C*N2
CCC(CC2)C(O)(c3ccccc3)c4ccccc4
In the classic procedure, the RNN samples freely tokens until the end of the SMILES is
reached. For scaffold constrained generation, the RNN is constrained to follow the SMILES
scaffold, and sampling is enabled only when an open position * of the SMILES is reached.
The major subtlety lies in the fact that the sampling procedure depends upon the con-
figuration of the molecular graph around the open position, especially with regard to the
decision to stop sampling and resume reading. In this work, we tackle three different kinds of
open positions. First, open positions at branching points of the molecular graph (commonly
referred to as R-groups). Then open positions in linkers (that link different cycles of the
molecule), and finally constrained choices, where the position is open but the number of
possibilities is already limited within the drug discovery project. Each kind of open position
requires an adequate sampling procedure. The general algorithm for scaffold constrained
9
sampling is the following:
Algorithm 2: Generating new SMILES samples with scaffold constraints
Result: SMILES string with scaffold s
Input: scaffold s = s1, ..., sn
initialize h0 ;
x0 = GO ;
t = 1 ;
for i← 1 to n do
if si not ∗ then
Read si and update ht−1 to ht ;
xt = si ;
t = t+ 1 ;
else
Sample y = (y1, ..., yk) and update h according to special sampling procedure
for scaffold decoration;
xt, ..., xt+k = y1, ..., yk ;
t = t+ k
end
t = t+ 1;
xt = EOS ;
Output: x0, ...xt
Decorating a fixed scaffold is one the predominant techniques used by medicinal chemists
in lead optimization28 and being able to perform this task with a generative model is of
major practical importance in their application to drug discovery. For branched decorations
(i.e R-groups), the SMILES translation is straightforward: opening and closing parentheses
denote the beginning and end of the branch, and therefore an open branched decoration
will translate to (*) in the SMILES language. In this case, the sampling procedure is easily
designed: the RNN is free to sample any tokens while the branch is open. When a closing
parenthesis that matches the opening parenthesis of the branch is sampled, then it means
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the RNN finished to sample the branched decoration, and can resume reading the rest of
the scaffold. This also implies that it is necessary to keep track of the opening and closing
parentheses sampled within the decoration. Another technical issue that arises due to the
SMILES language is that sampled cycles identifiers (1, 2, 3, ...) should be different than the
ones used in the scaffold, to ensure the respect of the given scaffold in corner cases where a
cycle opened before an open position is closed after said open position.
Algorithm 3: Decorating a scaffold on a given branching position
Result: Smiles string with completed decoration
Input: hidden state h
h′0 = h ;
opened = 1 ;
closed = 0;
t = 1;
while opened > closed do
Sample xt from P (x | h′t−1) and update h′t−1 to h′t ;
if x = ’(’ then
opened += 1 ;
else if x = ’)’ then
closed += 1 ;
t = t+ 1 ;
end
Additional refinements are possible, such as specifying the beginning of the branch (e.g
(CN*) instead of (*)), or restraining the branch to be a linear fragment (by forbidding the
opening of new branches and cycles).
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Figure 1: Sampling a new branch
If branched decorations represent the majority of modifications allowed on a scaffold
during lead optimization phases, it is sometimes interesting to allow more profound changes
on the scaffold by performing scaffold hopping.28 To tackle this particular task, we investigate
the possibility to have an open position within a linker between cycles. This problem presents
different difficulties. First, contrary to branched decorations, there is no clear indicator for
stopping sampling and resuming reading the pattern. Thus, the stopping criterion will
necessarily be arbitrary. We implement it under the form of a user-defined probability
distribution on the length of the added fragment. Furthermore, as the end of sampling
is arbitrarily decided rather than chosen by the RNN, we need to keep track of opening
and closing parentheses as well as cycles to ensure that branches and cycles are completed
within the added fragment before stopping sampling. The stopping criterion for sampling is
therefore a combination of a specified probability-distribution and if the sampled fragment
doesnt contains uncompleted cycles and branches. We do not look into the task of modifying
existing cycles, which is more complex.
The ability to modify the core of a molecule allows our method to tackle more than
simply scaffold decoration and thus to perform scaffold-hopping as well (see figure S1 for
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Algorithm 4: Scaffold hopping by linker completion
Input: hidden state h, distribution on linker size Psize
Result: Smiles string with completed linker
h′0 = h ;
Sample nchar from Psize ;
opened = 0 ;
closed = 0 ;
step = 0 ;
cycle = False ;
while cycle or step < nchar or opened > closed do
Sample xt from P (x|ht) and update h′t−1 to h′t;
if xt = ’(’ then
opened = opened + 1 ;
else if xt = ’)’ then
closed = closed + 1 ;
else if xt ∈ {1, 2, . . . , 9} then
if corresponding cycle not opened then
cycle = True ;
keep track of opened cycle ;
else
close corresponding cycle ;
if no cycle still opened then
cycle = False ;
step = step + 1;
end
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sampled molecules with a modified core, starting from the scaffold in Figure 2).
Figure 2: Scaffold hopping by sampling a new linker
Finally, a simple use case nonetheless of practical interest is when open positions are ac-
tually restricted to a small number of discrete choices. During lead optimization campaigns,
small variations on the scaffold are often encountered. Hence, we would like to keep this
variability when designing molecules, while restraining our choices to the few possibilities
that exist in this given context. The SMARTS25 language, an extension of SMILES, deals
with discrete choices with the following syntax: [x1, x2, ..., xk] represents a discrete choice
between SMILES characters x1, x2, ..., xk. We use this syntax for sampling between a finite
set of discrete choices. The sampling procedure is straightforward: restrict the possible to-
kens to those present in the discrete choices, renormalize the probability distribution and
then sample. Instead of drawing the next token from P (x|ht), we sample it from:
Q(x) = softmax[P (x|ht) ·
∑
c∈choices
δx, c] (2)
By design, our method can deal with multiple open positions of different nature within
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the same scaffold. This is important as scaffold constrained lead optimization often deals
with multiple open positions at once.
Experiments
The objective of the following experiments is to verify the ability of our method to perform
the major tasks that can be encountered in the context of scaffold-constrained molecular
generation. We first check the ability of our method to perform scaffold-constrained genera-
tion on previously unseen scaffolds. We then assess the capacity of our method to generate,
if needed, analogs to a given chemical series, in a focused learning task. Finally, we measure
its performance in optimization of molecules with given constraints by benchmarking it in
different scaffold-constrained goal-oriented scenarios.
We rely on different sets of molecule for training and validation of the method. Following
Olivecrona et al.13 1.2 million molecules extracted from the ChEMBL database and filtered
by drug-likeness related criteria, such as size, atoms, absence of macrocycles are used as a
training set. To validate the ability to generate molecules around new scaffolds, we look into
the SureChEMBL29 database, a database of patented molecules. Clustering molecules by
their Bemis-Murcko scaffold,30 we extract 18 chemical series with 18 (see figure S2) different
scaffolds. Those scaffolds are chosen for validation as they
• are sampled from real life drug discovery projects
• where not present in the training set (we remove any molecule that has one of the 18
scaffolds from the training set)
To study the ability to explore a focused region of chemical space and design analogs
to a given series, we also isolate the largest (93 molecules) among the extracted chemical
series. This yields 17 scaffolds for the validation set, and one scaffold for the focused learning
validation set. Below, we refer to the molecules extracted from ChEMBL as the training
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set, the chemical series from SureChEMBL as the validation set, and the chemical series
referenced above as the focused learning validation set.
To implement our model, we build on the existing codebase released by Olivecrona et al.
that already includes a SMILES based RNN, and with which many researchers are already
familiar. The RNN used in the subsequent tasks are either trained on the training set
(onwards named Generic RNN) or on the focused learning validation set chemical series
(named Focused RNN).
The rationale for using the Generic RNN in most applications is that the training set is
comprised of diverse drug-like compounds, and that an RNN trained on it should be able to
explore a large and varied chemical space. For the focused learning task, the goal is to assess
the ability to generate close analogs to a given chemical series, and therefore the Focused
RNN trained specifically on this chemical series is used.
For the task of generating molecules around an unseen scaffold, we use the Generic RNN
to design molecules conditioned on the different scaffolds in the validation set. Major met-
rics used in benchmarking suites4,14 for in-silico molecular generation are evaluated. The
main goal is to ensure the ability to generate valid and unique SMILES, as well as to assess
whether physico-chemical properties are similar to those of drug-like compounds. For the
focused learning task, we compare distributions of molecules generated by the Generic RNN
and the Focused RNN with the training set, validation set and the focused learning validation
set. As for goal-oriented benchmarks, we begin with the DRD2 target to provide a fair com-
parison with prior work22 21 on scaffold constrained generation and investigate the ability of
our method to generate predicted DRD2 actives on the different validation scaffolds studied
in.22 To generate optimized molecules, we rely on a state-of-the-art Reinforcement Learn-
ing procedure, hill-climbing.4 We then benchmark our method with the MMP-12 series31
which is a large publicly available industrial lead-optimization dataset. Scaffold constraints
are present in the dataset and explicitly mentioned in the original work that released the
data, which supports our statement that they are common within drug-discovery lead opti-
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mization campaigns. After building a QSAR model on pIC50 values, we compare our model
against SMILES based LSTM with hill-climbing,4 a state-of-the-art in-silico de-novo design
algorithm, in the task of generating predicted actives with the required scaffold.
Generating molecules with new scaffolds
To verify the ability of our method to generate novel molecules around unseen scaffolds, we
perform classic distribution learning benchmarks on sets of molecules designed around the
scaffolds from the validation set. For each of the 17 scaffolds, we generate 10 000 SMILES.
We first compute the proportion of (i) valid and (ii) unique SMILES. Validity is defined
as whether the SMILES defines a valid molecular structure and is checked with the RD-
Kit.32 We shall note that validity ensures that the SMILES is syntactically valid (all rings
and branches closed, no illegal atom types) but does not mean that the molecule will be
necessarily synthetizable in a wet-lab. We also compute several physico-chemical proper-
ties for each valid molecule generated: calculated logarithm of partition coefficient(logP),
Molecular Weight (MW), Synthetic Accessibility Score33 (SAS), Quantitative Estimate of
Drug-Likeness34 (QED), numbers of H donors (HBD) and acceptors (HBA). All properties
were computed with the RDKit.32 We group molecules generated for each of the differ-
ent scaffolds together and compare the distributions of those properties between generated
molecules, the training set and the validation set.
The proportion of unique and valid molecules for each scaffold in the validation set are
given Figure 3, where the scaffolds are ordered by increasing number of open positions.
Validity and uniqueness proportions (calculated over 10 000 SMILES for each scaffold),
shown in Figure 3, are on par with the best scores obtained by various generative models.4
Scaffolds in the validation set are ordered by ascending number of open positions; uniqueness
proportion increases with the number of open positions, which matches the intuition that the
more possibilities there is to modify the scaffolds, the more diverse the generated SMILES
will be for a given scaffold.
17
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Scaffold index
0.0
0.2
0.4
0.6
0.8
1.0
V
al
id
it
y
an
d
u
n
ic
it
y
Validity
Unicity
Figure 3: Proportions of valid and unique molecules out of 10000 generated for each valida-
tion scaffold
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Figure 4: Validity and uniqueness proportions (min, lower quartile, median, upper quartile
and max) across the 17 validation scaffolds
We then perform comparison of distributions of various properties as a sanity check to
ensure that generated molecules are similar to the drug-like molecules of the training and
validation set.
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Figure 5: Histogram of properties across generated molecules, training and validation set.
For molecular weight and ClogP, values outside the [250,750] g.mol−1 and [-1,6] ranges are
not shown, and bars are the extremities accumulate values outside those ranges.
We note that properties are distributed similarly for the different sets of molecules, sug-
gesting that generated molecules populates a similar property space as the training and
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validation set. An interesting fact is that generated molecules have lower QED scores; this is
rather intuitive as molecules from training and validation set are actual molecules implying
the bias that they were necessarily synthesizable and considered interesting enough in a drug
discovery context so that their synthesis was actually performed.
Focused learning on a chemical series
In the context of lead-optimization, we might like to narrow the search for optimized
molecules in a focused chemical space. Therefore, we investigate whether we could generate
close analogs to an existing chemical series. We use the Focused RNN, trained specifically
on the focused learning validation set (comprised of a single chemical series), to generate
molecules with the scaffold of the focused learning validation set. For comparison, we also
generate molecules with the same scaffold but using the Generic RNN.
We then perform dimensionality reduction to 2D with PCA on ECFP4 fingerprints.
Generated molecules are plotted in Figure 6 against the focused learning validation set and
the training set.
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Figure 6: PCA of generated molecules with Focused and Generic RNN compared with
training set and focused learning validation set
Molecules generated with the Generic RNN overlap almost completely with the training
set, while molecules generated with the Focused RNN overlap with the Focused learning
validation series. This indicates that using a focused RNN allows to sample a chemical space
close to a chemical series of interest.
It should be noted that while dimensionality reduction such as PCA on fingerprints is
commonly used to compare distributions of molecules,12 the question of whether this is the
most relevant approach (especially as fingerprints are high-dimensional and binary) is still
open, and should be kept in mind, as well as the fact that we are also comparing molecules
21
with a shared substructure.
Generating DRD2 actives
Benchmarking our model on goal-oriented tasks is the main focus of our experiments. A
benchmark for goal-oriented scaffold-constrained generation was proposed by Aru´s-Pous
et al.. We therefore start by tackling the same task, which is generating predicted ac-
tives on the DRD2 target with specific scaffolds. We use the same 5 validation scaffolds.
First, we assess unicity and validity proportions of generated molecules to ensure that our
method generalizes well to those scaffolds. Then, for each scaffold, we run a reinforcement
learning procedure, hill-climbing, with the objective of generating predicted actives. Activity
prediction is done with the QSAR model from.13 After ten epochs dedicated to learning to
generate predicted actives, the best 50 molecules are kept.
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Table 3: Metrics on distribution learning and goal-oriented learning for DRD2 validation
scaffolds
Scaffold Valid
molecules
Unique
molecules
Predicted ac-
tive molecules
out of 50 best
86% 84% 100%
82% 92% 100%
86% 96% 100%
92% 90% 100%
98% 32% 100%
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Comparison with the Reinvent Scaffold Generator was not direct 1, as no insight was
given of the total number of molecules generated for each scaffold. As mentioned previously,
we made the choice to assess the top 50 best molecules generated. Nonetheless, we find that
our model is able to generate a much higher proportion of predicted actives for each scaffold.
This is achieved even without access to known actives on DRD2 with different scaffolds,
unlike in Aru´s-Pous et al. where training with actives is required. Furthermore, relying on a
much simpler architecture translates into a much higher throughput for generated molecules
(roughly 100 times faster in CPU-time). Contrary to the Reinvent Scaffold Generator, we
also do not require the use of a special preprocessing algorithm or of specific pretraining. On
the other hand, we require a Reinforcement Learning procedure to be ran, though it comes at
a rather cheap computational cost (in the limit that the property of interest can be computed
efficiently). This allows us to be much more efficient in finding molecules optimizing a given
objective.
Table 4: Speed of generation comparison
CPU time for generating 1000
molecules
Molecules generated per second
(CPU time)
Reinvent
Scaffold
Decorator
620.9 seconds 1.6 molecules/seconds
Scaffold-
constrained
generator
7.02 seconds 143 molecules/seconds
1comparison with21 is not provided as we failed to make use of the code released to replicate the findings
of this work
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A lead-optimization use case: the MMP-12 series
Experiments on the DRD2 target shows that our method can design predicted actives on
a biological target while satisfying scaffold constraints. To provide further comparison, we
designed a novel benchmark on the MMP-12 series, a publicly available industrial lead-
optimization dataset, and assessed how scaffold-constrained generation fares against a state-
of-the-art generative model. As goal-oriented models primary target is lead-optimization,
designing a benchmark that resembles the industrial problem wed like to solve makes sense.
We compare our method and classic SMILES-based RNN with hill climbing reinforcement
learning.4 For each method, 10 runs of reinforcement learning are launched, with the exact
same optimization procedure and number of steps to ensure a fair comparison. For each
run, the top 50 molecules are kept. For each molecule, given its predicted pIC50, the score
is computed as:

max(1, 1− (7.5− pIC50)/7.5), if scaffold constraints are met
0, otherwise
Molecules that have predicted pIC50 > 7.5 while respecting the scaffold constraint have
therefore a score of 1.
We report for each method, the percentage of actives (predicted pIC50 > 7.5) with sub-
structure (therefore matching 2/2 of the projects requirements), only actives (1/2 require-
ments) , only matching substructures (1/2 requirements as well) and none of the two (0/2
requirements met).
With our method, we find 23% of molecules that satisfy 2/2 requirements for the project
while no satisfying molecules are found with classic SMILES-based RNN. This discrepancy
is probably due to the fact that the chemical space where the structure constraint is met is
a very sparse subspace of chemical space, which hinders the performance of reinforcement
learning. This leads the classic RNN to struggle generating molecules within this chemical
space while optimizing activity. On the contrary, our method generates by design only
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Table 5: Generating actives on the MMP-12 series
Right scaffold,
active (2/2)
Right scaffold,
not active (1/2)
Active, without
scaffold (1/2)
Not active,
without scaffold
(0/2)
Classic RNN 0% 56% 42% 2%
Scaffold-
constrained
generator
23% 77% 0% 0%
molecules that meet the scaffold requirement, allowing the optimization procedure to focus
only on the true objective. Amongst the molecules discovered by our method are present
some experimentally validated actives that were part of the held-out validation set, yielding
yet another confirmation that inverse QSAR powered by generative models can discover
experimentally validated molecules.
Figure 7: Re-discovered active from the held-out validation set, with the scaffold constraint
highlighted
This experiment shows that, by releasing the structure constraint (as it is built in our
model), our method can search much more efficiently for optimized molecules (w.r.t predicted
activity) within a subspace of molecules with a required scaffold. This experiment also shows
that optimization under structure constraints seems to be a difficult task for generative
models. For instance, on the Guacamol4 benchmarking suite, optimization on multiple
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objectives is not problematic and high scores are achieved on a wide range of tasks by
SMILES-based RNN. Yet, having only two objectives in this task with one being a scaffold
constraint, classic SMILES-based RNN struggles to generate optimized molecules, which
gives a significant advantage to scaffold constrained generation. As scaffold constraints are
common within drug discovery projects, we think that our method could therefore prove to
be very useful in this context.
Conclusion
Applying generative models to drug-discovery can be used in lead optimization tasks, that
often require to respect scaffold constraints. Those constraints are mainly present for pre-
serving biological activity and staying in known SAR domains for the optimized properties,
as well as for synthesizability and optimization of the synthesis process. Including those
constraints in the generative process of a model is a difficult problem, and that has potential
practical impact on the applications of generative models to drug-discovery. In this work, we
investigate how a well-known model, SMILES-based RNN, can be slightly modified to achieve
different scaffold-constrained generative tasks. This is possible thanks to a modified sampling
procedure. Our approach for scaffold constrained generation thus doesnt require designing
a new model, or even retraining it. Furthermore, all previous works on reinforcement learn-
ing for molecular properties optimization with SMILES-based RNN stay applicable. Using
distribution learning benchmarks, we show that our method can generalize across unseen
scaffolds, and can also generate molecules in a focused fashion. The validation scaffolds used
for this task are extracted from SureChEMBL and thus derived from real lead optimization
chemical series. On scaffold constrained goal-oriented benchmarks, our method largely out-
performs state-of-the-art de-novo design algorithms. Our approach was able to generate new
predicted actives on the DRD2 target, without specific pretraining. Furthermore, we showed
that it outperformed classic SMILES based reinforcement learning for designing predicted
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actives on the MMP-12 series, proposing held-out experimentally validated actives. We also
show that by design, reinforcement learning methods are applicable in this context. This
enables our method to use state-of-the-art algorithms for goal-oriented tasks, and we show
strong performance on scaffold constrained in-silico molecular optimization. Our model also
goes beyond simple scaffold decoration. It can provide low level control on the way the scaf-
fold is completed, and can also be used in other tasks such as scaffold hopping. Limitations
of the method include the need to handcraft the scaffold constraints in SMILES format, as
well as the fact that in particular instances, specificities of the SMILES language requires
manual overriding of sampled cycles to ensure the respect of scaffold constraints. Overall, we
believe our method shows a real practical interest for scaffold constrained optimization tasks
that make the most of actual lead optimization challenges in drug discovery. Coupled with
the fact that we rely on a well-known and already widely adopted model, we expect that it
will benefit researchers looking to apply generative models for lead optimization tasks.
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Data curation and software availability
Code availability
All software and data to reproduce the results of this paper are available at:
https://github.com/maxime-langevin/scaffold-constrained-generation.
To implement the methods presented above, we build on the existing codebase of ?, avail-
able at https://github.com/MarcusOlivecrona/REINVENT. The different experiments are
reproduced in Jupyter notebooks? available in our codebase. An extra notebook show-
ing basic usage for researchers interested in simply using our method without necessarily
reproducing our results is also available.
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ChEMBL dataset
The ChEMBL? database is often used to train generative models of drug-like molecules. To
train our RNN, we use a preprocessed version of the ChEMBL? where only molecules having
between 10 and 50 heavy atoms and comprised of elements ∈ {H,B,C,N,O, F, Si, P, S, Cl, Br, I}
were kept. The original filtered ChEMBL dataset can be found and downloaded at: https://
github.com/MarcusOlivecrona/REINVENT/blob/master/data/ChEMBL_filtered, and in
our repository at https://github.com/maxime-langevin/scaffold-constrained-generation/
data/ChEMBL_filtered. Furthermore, we filtered the dataset to exclude molecules having
one the 17 validation scaffolds as a substructure, yielding the final dataset at https://
github.com/maxime-langevin/scaffold-constrained-generation/data/ChEMBL_without_
sureChEMBL.smi.
SureChEMBL dataset
The SureChEMBL? database is comprised of patented compounds. The database can be
downloaded at https://chembl.gitbook.io/chembl-interface-documentation/downloads.
34000 compounds were exctracted from SureChEMBL v2019.10.01. Compounds were clus-
tered by Bemis-Murcko scaffold? and 18 chemical series (every molecule in each series hav-
ing the same scaffold) were kept to be used as a validation set. The molecules in the 18
series can be found at https://github.com/maxime-langevin/scaffold-constrained-
generation/data/SureChEMBL/200323_SureChemBL_dataset_636.sdf, and the 18 scaf-
folds at https://github.com/maxime-langevin/scaffold-constrained-generation/data/
SureChEMBL/surechembl_scaffolds.sdf.
DRD2 dataset
The full DRD2 dataset can be found at https://github.com/undeadpixel/reinvent-
scaffold-decorator/blob/master/training_sets/drd2.excapedb.smi.gz . The scaf-
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folds used for the goal-directed benchmark are the ones used in ?, and can be found in our
codebase at https://github.com/maxime-langevin/scaffold-constrained-generation/
data/DRD2/drd2_scaffolds.sdf.
MMP-12 dataset
The MMP-12 dataset was downloaded from the supplementary materials of ?. The dataset
can be found at https://github.com/maxime-langevin/scaffold-constrained-generation/
data/MMP12/mmp12.csv.
Implementation details
Computation time benchmarks
Computation time benchmarks were run on an Amazon EC2 p2.xlarge, and assessed the
runtime of generating molecules using one CPU.
Distribution learning benchmarks
To assess distribution learning benchmarks, 10000 molecules were generated for each scaffold.
Validity
The validity score for a scaffold is the ratio of the number of valid molecules, as defined in
the RDKit,? out of all 10000 generated molecules.
Unicity
Out of the generated valid molecules, the number of unique molecules is computed as the
ratio of molecules with distinct canonical SMILES string.
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Physico-chemical properties
All physico-chemical properties where computed using the RDKit. Properties were com-
puted on the valid molecules out of the 10000 generated for each scaffold, and then grouped
together. The overall distributions were plotted against the distributions of both the train-
ing and the validation set, in order to check that there was no striking dissimilarity between
them.
Predicting DRD2 activity
One of the major point of the DRD2 activity was to benchmark our method against the
Reinvent Scaffold Decorator.? Thus, it seems natural to use the same QSAR model. As we
weren’t able to find this QSAR model within the codebase reproducing the experiments of
the article, we used a QSAR model? used in a work from the same group on the DRD2
dataset, and we assumed that the QSAR model used in the two works was the same. In our
codebase, the model used for DRD2 activity prediction can be found at https://github.
com/maxime-langevin/scaffold-constrained-generation/data/clf.pkl
Predicting MMP-12 activity
To predict activity on the MMP-12 target, the dataset was split into a training and a test
set. Then, a random forest regression algorithm (implemented with Scikit-learn? ) was fit-
ted on the training set with continuous targets (corresponding to the experimental pIC50),
and evaluated on the testing set. The evaluation yielded a coefficient of determination
r2 = 0.84. The QSAR model is accessible at https://github.com/maxime-langevin/
scaffold-constrained-generation/data/MMP12/final_activity_model.pkl, and eval-
uation on the test set at https://github.com/maxime-langevin/scaffold-constrained-
generation/MMP12_experiments.ipynb.
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Hill climbing procedure
To optimize molecules in goal-oriented benchmarks, a hill-climbing procedure? was used,
as it was shown to be overall the best method amongst different generative models. The
algorithm can be summarized as a repetition of the following steps:
• Generate 500 molecules
• Score them and keep the top 50 unique molecules
• Perform 10 rounds of log-likelihood maximization with the 50 best molecules
Those steps are repeated 10 times in a row. The code for performing hill-climbing can be
found at https://github.com/maxime-langevin/scaffold-constrained-generation/hill_
climbing.py.
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Figures
Figure S1: Molecules obtained after modifying the core of fexofenadine. The scaffold con-
straint is highlighted.
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Figure S2: Validation scaffolds from SureChEMBL
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